Biomerica Says Data From Pivotal Clinical Trial Evaluating InFoods IBS Test In Treating IBS Sufferers Published In June 2025 Issue Of Gastroenterology

• Landmark Peer-Reviewed Study Demonstrates Effectiveness of Personalized Dietary Therapy for IBS Patients Using inFoods® IBS Test.
• Gastroenterology, the premier journal in gastrointestinal science, features data supporting inFoods IBS as an effective personalized, non-drug approach for managing IBS.
• Study results suggest inFoods IBS could be particularly beneficial for IBS-M patients, a population with no current FDA-approved drug treatments.

IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global leader in advanced diagnostic-guided therapies, today announced that data from its pivotal clinical trial evaluating the inFoods® IBS test in treating IBS sufferers has been published in the June 2025 issue of Gastroenterology, the official journal of the American Gastroenterological Association and the highest-impact publication in the GI field.

The randomized, multicenter, double-blind, placebo-controlled trial demonstrated that patients with Irritable Bowel Syndrome (IBS) experienced statistically significant improvement in symptoms—particularly abdominal pain and bloating—when following a personalized elimination diet guided by the inFoods IBS test. The test identifies specific foods that provoke an abnormal immune response, believed to be a key trigger of IBS symptoms.

Key Findings Highlighted in Gastroenterology

The trial included 238 patients across eight U.S. academic centers (including Mayo Clinic, Clevland Clinic and Univ. of Michigan), comparing outcomes between a treatment group who eliminated foods identified by the inFoods IBS test versus a control group following a placebo "sham" diet.

• 59.6% of patients in the treatment group achieved the FDA responder definition for abdominal pain reduction, compared to 42.2% in the control group
• Among patients with IBS-C, 67.1% in the treatment arm reached this benchmark vs. 35.8% in controls
• Among those with IBS-M, 66.0% in the treatment group met the target vs. 29.5% in controls

These results suggest inFoods IBS could be particularly beneficial for IBS-M patients, an underserved group, for whom there are currently no FDA-approved drug treatments. IBS-M patients are estimated to represent approximately 33% of the IBS market.